Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer
Journal of Controlled Release · 2025
DOI: 10.1016/j.jconrel.2025.02.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025. Verfasst von Xue Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130061, PR China; Key Labora…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Benzimidazoles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jilin University, Jilin Provincial Scientific and Technological Development Program.
Abstract (Originalsprache)
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) selectively arrest malignant cells in the G1 phase of cell cycle by inhibiting CDK4/6-mediated phosphorylation of retinoblastoma protein. However, CDK4/6i therapy is often ineffective against triple-negative breast cancer (TNBC) due to the high lysosomal content in TNBC cells, which sequesters the drugs and prevents them from reaching their nuclear target. To address this challenge, three pH- and glutathione-responsive poly(amino acid) nanogels composed of methoxy poly(ethylene glycol) of various lengths and poly(L-glutamic acid-co-L-cystine) (mPEG-P(Glu10-co-Cys25)) were developed to efficiently deliver the CDK4/6i abemaciclib (ABE) to TNBC cells. These nanogels bypassed lysosomal sequestration, thereby enhancing the efficacy of molecularly targeted immunotherapy. Among the nanogels, the formulation with mPEG2000 (NG2000) exhibited the highest efficiency in delivering ABE, resulting in increased cell apoptosis, activation of an anti-cancer immune response, reduction of immunosuppression, and improved therapeutic outcomes against TNBC. Furthermore, NG2000/ABE enhanced immune checkpoint therapy for TNBC, achieving a tumor inhibition rate of 89.66%. These findings demonstrate the potential of poly(amino acid) nanoformulations for delivering CDK4/6 inhibitors as molecularly targeted immunotherapy for TNBC in clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130061, PR China; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry…
- Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130061, PR China. Electronic address: yangming@jlu.edu.cn.
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China.
- Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Beijing 100730, PR China.
- Department of Chemistry, Northeast Normal University, 5268 Renmin Street, Changchun 130024, PR China.
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130061, PR China. Electronic address: yahui@jlu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Jilin University
- Jilin Provincial Scientific and Technological Development Program
Zitieren
APA
Wei, X., Yang, M., Zou, H., Shen, S., Li, Y., Chen, L., Liu, Y., Li, D., & Ding, J. (2025). Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.02.020
Vancouver
Wei X, Yang M, Zou H, Shen S, Li Y, Chen L, et al. Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.02.020
BibTeX
@article{Wei2025,
author = {Wei, Xue and Yang, Ming and Zou, Haoyang and Shen, Songjie and Li, Yuechong and Chen, Li and Liu, Yahui and Li, Di and Ding, Jianxun},
title = {Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer},
journal = {Journal of Controlled Release},
year = {2025},
doi = {10.1016/j.jconrel.2025.02.020}
}
EUVIMED